Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
Dan W. Reynolds, PhD
Advertisement
Dan W. Reynolds, PhD, is a research investigator II in the chemical development analytical sciences department at GlaxoSmithKline, Five Moor Dr., PO Box 13398, Research Triangle Park, NC 27709.
Articles by Dan W. Reynolds, PhD
Advertisement
Latest Updated Articles
- Available Guidance and Best Practices for Conducting Forced Degradation Studies
Published: February 1st 2002 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
2
Standardizing Operations to Meet Global Sustainability and Resilience Goals
3
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
4
US and European Pharma Manufacturing Face Diverging Paths to Resilience
5
